Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GSK's Lost Quarter: $3 Billion DoJ Settlement Far Outstrips Net Profit

This article was originally published in The Pink Sheet Daily

Executive Summary

If approved, the settlement would set a new record for the pharmaceutical industry in its dealings with the federal government, but would be covered by the firm's existing reserves.

You may also be interested in...

EU Pharma Ups Share Buybacks In 2012

Share buybacks are controversial in the biopharma industry, but European pharma companies, facing tough operating environments and pressures on near-term financials, are planning to invest in them in 2012 more than in recent years.

GSK’s Deal With DoJ Is Fourth In Eight Years; Exec Liability Uncertain

GlaxoSmithKline PLC’s toughest negotiations this year have been with the federal government.

No End In Sight: Pharma Companies Continue To Face Government Probes

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts